Levobupivacaine Altan Pharma

Levobupivacaine, the active ingredient in Levobupivacaine Altan Pharma, is a local anesthetic (amide) presented as a sterile solution for epidural use. It provides regional nerve block anesthesia for surgical procedures, obstetric analgesia, and postoperative pain management in adult patients.

GNH USA supplies Levobupivacaine Altan Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements. The product is manufactured under EU GMP guidelines and distributed through a secure cold‑chain where required.

Levobupivacaine is employed in regional anesthesia and pain control through epidural and peripheral nerve block techniques. - Regional anesthesia: provides dense sensory and motor block for surgical procedures requiring nerve blockade. - Epidural analgesia: delivers continuous pain relief during labor, delivery, or postoperative periods. - Surgical anesthesia: facilitates anesthesia for operations where a rapid onset and prolonged duration are needed.

Adverse reactions to levobupivacaine may vary in frequency and severity.

Common Side Effects: - Hypotension: decreased blood pressure following epidural administration. - Bradycardia: slowed heart rate observed during or after dosing. - Dizziness: transient light‑headedness or vertigo. - Nausea: mild gastrointestinal upset. - Metallic taste: transient alteration in taste perception. - Headache: post‑dural puncture or medication‑related headache.

Serious or Rare Side Effects: - Cardiac arrest: severe cardiotoxicity leading to loss of cardiac function. - Seizures: central nervous system excitation causing convulsions. - Respiratory depression: reduced breathing effort requiring support. - Allergic reactions: rash, urticaria, or anaphylaxis. - Prolonged motor block: extended loss of muscle function beyond expected duration. - Methemoglobinemia: abnormal hemoglobin causing reduced oxygen delivery.

When using levobupivacaine, clinicians should observe several safety precautions to minimize risks. - Cardiac monitoring: observe ECG and blood pressure continuously during administration. - Avoid intravascular injection: aspirate before injection and monitor for signs of systemic toxicity. - Hepatic impairment: adjust dose or monitor closely in patients with liver dysfunction. - Elderly patients: use reduced initial doses due to increased sensitivity. - Store at ambient temperature: keep in original container, protect from light and moisture.

Levobupivacaine may interact with other medicines, affecting its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): increase risk of cardiotoxicity. - Beta‑blockers: may exacerbate bradycardia and hypotension. - High‑dose general anesthetics (e.g., propofol): additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Opioids: enhanced respiratory depression when combined. - NSAIDs: potential increase in bleeding tendency. - Magnesium sulfate: potentiates neuromuscular blockade.